A Dose-finding, Multi-centre, Double-blind, Randomised, Parallel, Placebo-controlled Trial to Investigate Efficacy and Safety of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH).

Trial Profile

A Dose-finding, Multi-centre, Double-blind, Randomised, Parallel, Placebo-controlled Trial to Investigate Efficacy and Safety of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH).

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2015

At a glance

  • Drugs Degarelix (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Acronyms DELUTS
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 06 Apr 2011 Planned end date changed from Apr 2011 to May 2011 as reported by ClinicalTrials.gov.
    • 14 Feb 2011 Planned end date changed from 1 Jul 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top